KR-20260067638-A - COMPOSITION FOR INHIBITING HEPATITIS B VIRUS(HBV) PROLIFERATION

Abstract

The present invention relates to a composition for inhibiting HBV proliferation comprising a compound represented by the following chemical formula 1 as an active ingredient: [Chemical Formula 1] (In the above chemical formula 1, R is a substitutable C3 - C20 cycloalkyl group or a substitutable C6 - C20 aryl group, and The above substitution is by oxygen, nitrogen, sulfur, hydroxy, linear or branched C1 - C6 alkyl, C3 - C20 cycloalkyl, C6 - C20 aryl, halogen, or a combination thereof).

Inventors

• 김경민
• 김은하
• 박주영
• 사자드 무하마드 아자르
• 칼숨 파디아
• 송찬호
• 하지선
• 허연정

Assignees

• 아주대학교산학협력단
• 대한민국(질병관리청 국립보건연구원장)

Dates

Publication Date

20260513

Application Date

20241106

Claims (12)

1. A composition for inhibiting HBV proliferation comprising a compound represented by the following chemical formula 1 as an active ingredient: [Chemical Formula 1] (In the above chemical formula 1, R is a substitutable C3 - C20 cycloalkyl group or a substitutable C6 - C20 aryl group, and The above substitution is by oxygen, nitrogen, sulfur, hydroxy, linear or branched C1 - C6 alkyl, C3 - C20 cycloalkyl, C6 - C20 aryl, halogen, or a combination thereof).
2. In Article 1, A composition for inhibiting HBV proliferation, wherein the compound represented by the above chemical formula 1 comprises any one of the following compounds: ; .
3. In Article 1, The inhibition of HBc (Hepatitis B core) protein expression in HepG2 cells by a compound represented by the above chemical formula 1, Composition for inhibiting HBV proliferation.
4. In Article 1, The formation of nucleocapsid in HepG2 cells is inhibited by a compound represented by the above chemical formula 1, Composition for inhibiting HBV proliferation.
5. In Article 1, HBV DNA synthesis in HepG2 cells is inhibited by a compound represented by the above chemical formula 1, Composition for inhibiting HBV proliferation.
6. In Article 1, HBV DNA synthesis in Huh7 cells is inhibited by a compound represented by the above chemical formula 1, Composition for inhibiting HBV proliferation.
7. A pharmaceutical composition for preventing or treating HBV infection, comprising a composition for inhibiting HBV proliferation according to any one of claims 1 to 6.
8. In Article 7, The above pharmaceutical composition for the prevention or treatment of HBV infection further comprises a pharmaceutically acceptable carrier.
9. In Article 8, A pharmaceutical composition for the prevention or treatment of HBV infection, wherein the carrier comprises a substance selected from the group consisting of lactose, dextrose, sucrose, sorbitol, mannitol, starch, acacia gum, calcium phosphate, alginate, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, syrup, methyl cellulose, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, menthol, mineral oil, and combinations thereof.
10. In Article 7, The above pharmaceutical composition for preventing or treating HBV infection further comprises a component selected from the group consisting of preservatives, solubilizers, stabilizers, humectants, sweeteners, coloring agents, flavoring agents, salts, buffers, antioxidants, lubricants, emulsifiers, suspending agents, preservatives, and combinations thereof.
11. In Article 7, The above pharmaceutical composition for the prevention or treatment of HBV infection is administered by a method selected from the group consisting of intraperitoneal administration, oral administration, inhalation administration, intravenous administration, intramuscular administration, subcutaneous administration, dermal administration, intrauterine administration, tumor administration, rectal administration, and combinations thereof.
12. A health functional food for preventing or improving HBV infection, comprising a compound represented by Chemical Formula 1 of Claim 1 as an active ingredient.

Description

Composition for Inhibiting Hepatitis B Virus (HBV) Proliferation The present invention relates to a composition for inhibiting the proliferation of hepatitis B virus (HBV). Hepatitis B virus (HBV) is one of the major pathogens causing serious health problems worldwide. According to the World Health Organization (WHO), approximately 250 million people are infected with chronic hepatitis B, and about 900,000 people die each year from hepatitis B-related complications. Currently, nucleoside/nucleotide analogs and interferon-alpha are primarily used to treat hepatitis B. However, these treatments have drawbacks, such as difficulty in achieving complete viral elimination, the development of resistance with long-term administration, and side effects. Therefore, there is an urgent need for the development of anti-HBV drugs with novel mechanisms of action. Recent studies have revealed that the sirtuin protein family plays a crucial role in the HBV life cycle. In particular, Sirtuin 2 (SIRT2) is known to act as an important regulator in the process of HBV replication. Consequently, interest in developing inhibitors targeting SIRT2 is growing. AGK2 is one of the well-known SIRT2 inhibitors that demonstrated an inhibitory effect on HBV proliferation in in vitro experiments; however, its clinical application has been limited due to low selectivity and side effects. Therefore, there is a need for research to improve the efficacy of inhibiting HBV proliferation and reduce side effects through the development of new variants based on the structure of AGK2. Korean Patent Publication No. 10-2020-0123392, which is the background technology of the present invention, relates to a composition for inhibiting the proliferation of hepatitis B virus and a method thereof. Figure 1 is the NMR spectrum of a compound according to Example 1 of the present invention. Figure 2 is the NMR spectrum of a compound according to Example 2 of the present invention. Figure 3 is the result of a cytotoxicity test according to one experimental example of the present invention. Figure 4 is the result of an experiment on the inhibition of HBV proliferation in a liver cancer cell line of Chemical Formula 1 according to one experimental example of the present invention. Figure 5 is an experiment on the inhibition of HBV proliferation in a liver cancer cell line of Formula 2 according to one experimental example of the present invention. Embodiments of the present invention are described below with reference to the attached drawings to enable those skilled in the art to easily implement the invention. However, the present invention may be embodied in various different forms and is not limited to the embodiments described herein. Furthermore, in order to clearly explain the present invention in the drawings, parts unrelated to the explanation have been omitted, and similar parts throughout the specification are denoted by similar reference numerals. Throughout this specification, when a part is described as being "connected" to another part, this includes not only cases where they are "directly connected," but also cases where they are "electrically connected" with other elements interposed between them. Throughout the entire specification, when a component is described as being located "on," "on top," "on top," "under," "on bottom," or "on bottom" of another component, this includes not only cases where the component is in contact with the other component but also cases where another component exists between the two components. Throughout this specification, when a part is described as "comprising" a certain component, this means that, unless specifically stated otherwise, it does not exclude other components but may include additional components. As used herein, terms of degree such as “about,” “substantially,” etc., are used to mean at or near the stated value when inherent manufacturing and material tolerances are presented in the stated meaning, and are used to prevent unscrupulous infringers from unfairly exploiting the disclosure in which precise or absolute values are mentioned to aid in understanding the invention. Furthermore, throughout this specification, “a step of” or “a step of” does not mean “a step for”. Throughout this specification, the term “combination thereof” included in the Markush-type expression means one or more mixtures or combinations selected from the group consisting of the components described in the Markush-type expression, and means including one or more selected from the group consisting of said components. Throughout the entire specification, the description "A and/or B" means "A, B, or A and B". Hereinafter, the composition for inhibiting HBV proliferation of the present invention will be described in detail with reference to the embodiments, examples, and drawings. However, the present invention is not limited to these embodiments, examples, and drawings. As a technical means for achieving the above-mentioned technica